Mouse only (wild-type C57BL/6J and mdx disease model); NHP only in non-GLP supporting studies
“The following toxicology studies were conducted to evaluate the safety of ELEVIDYS following administration in WT and mdx mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 31Source ↗
Why that species
Disease-model rodents (mdx mice, Dmdmdx rats) used to show micro-dystrophin expression and efficacy; no explicit species-relevance argument
“The pharmacology studies of ELEVIDYS were conducted in rodent models of DMD including mdx mice and Dmdmdx rats.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Surrogate molecule
No surrogate; clinical vector (Process B) tested in WT and mdx mice
“A 12-week GLP toxicology and biodistribution study (Report No. SR-20-066) evaluated single IV administration of 1.33 × 1014 and 4.01 × 1014 vg/kg ELEVIDYS (manufactured by Process B at Catalent) in 7 to 8 weeks old C57BL/6J WT and mdx mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗